In conclusion, we demonstrated that CSAD is involved in the development of NAFLD as a protective factor, which suggested that CSAD has the potential to become a new target for drug discovery in NAFLD. Here, CSAD is linked to metabolic dysfunction-associated steatotic liver disease.